慢性阻塞性肺疾病患者增加肌肉量：一项正在进行的工作。
Gaining muscle mass in COPD: a work in progress.
作者信息
McAuley Hamish J C, Maddocks Matthew
机构信息
Institute of Lung Health, University of Leicester, Leicester, UK.
Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King's College London, London, UK.
出版信息
ERJ Open Res. 2023 Jul 31;9(4). doi: 10.1183/23120541.00336-2023. eCollection 2023 Jul.
Abstract
摘要
https://bit.ly/3WI5Sjg. （此为网址，无法翻译为中文，保留原文即可）
相似文献
1
Gaining muscle mass in COPD: a work in progress.慢性阻塞性肺疾病患者增加肌肉量：一项正在进行的工作。
ERJ Open Res. 2023 Jul 31;9(4). doi: 10.1183/23120541.00336-2023. eCollection 2023 Jul.
2
Effects of Exercise Intervention on Peripheral Skeletal Muscle in Stable Patients With COPD: A Systematic Review and Meta-Analysis.运动干预对稳定期慢性阻塞性肺疾病患者外周骨骼肌的影响：一项系统评价和荟萃分析
Front Med (Lausanne). 2021 Nov 18;8:766841. doi: 10.3389/fmed.2021.766841. eCollection 2021.
3
Changes in lower limb muscle function and muscle mass following exercise-based interventions in patients with chronic obstructive pulmonary disease: A review of the English-language literature.运动干预对慢性阻塞性肺疾病患者下肢肌肉功能和肌肉量的影响：对英文文献的综述。
Chron Respir Dis. 2018 May;15(2):182-219. doi: 10.1177/1479972317709642. Epub 2017 Jun 5.
4
Effects of eccentric, concentric and eccentric/concentric training on muscle function and mass, functional performance, cardiometabolic health, quality of life and molecular adaptations of skeletal muscle in COPD patients: a multicentre randomised trial.离心、向心和离心/向心训练对 COPD 患者肌肉功能和质量、功能表现、心肺代谢健康、生活质量和骨骼肌分子适应的影响：一项多中心随机试验。
BMC Pulm Med. 2022 Jul 19;22(1):278. doi: 10.1186/s12890-022-02061-4.
5
Interleukin 33: a suitable target for biological therapies of COPD?白细胞介素33：慢性阻塞性肺疾病生物治疗的合适靶点？
ERJ Open Res. 2024 Sep 23;10(5). doi: 10.1183/23120541.00433-2024. eCollection 2024 Sep.
6
A randomized clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD.一项针对 COPD 患者的靶向营养辅助运动训练的疗效的随机临床试验。
J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):748-758. doi: 10.1002/jcsm.12219. Epub 2017 Jun 12.
7
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区，服用抗叶酸抗疟药物的人群中，叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
8
The importance of addressing physical activity and exercise intolerance in our patients with COPD.解决慢性阻塞性肺疾病（COPD）患者身体活动及运动不耐受问题的重要性。
Breathe (Sheff). 2024 Jun 11;20(2):230272. doi: 10.1183/20734735.0272-2023. eCollection 2024 Jun.
9
Respiratory and Limb Muscle Dysfunction in COPD.慢性阻塞性肺疾病中的呼吸和肢体肌肉功能障碍
COPD. 2015 Aug;12(4):413-26. doi: 10.3109/15412555.2014.974737.
10
Are the "critical" inspiratory constraints actually decisive to limit exercise tolerance in COPD?“关键”的吸气限制因素真的对限制慢性阻塞性肺疾病（COPD）患者的运动耐量起决定性作用吗？
ERJ Open Res. 2020 Aug 17;6(3). doi: 10.1183/23120541.00178-2020. eCollection 2020 Jul.
本文引用的文献
1
Efficacy of interventions to alter measures of fat-free mass in people with COPD: a systematic review and meta-analysis.改变慢性阻塞性肺疾病患者去脂体重指标的干预措施的疗效：一项系统评价和荟萃分析
ERJ Open Res. 2023 Jul 31;9(4). doi: 10.1183/23120541.00102-2023. eCollection 2023 Jul.
2
Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial.选择性雄激素受体调节剂治疗慢性阻塞性肺疾病肌肉无力：一项随机对照试验。
Thorax. 2023 Mar;78(3):258-266. doi: 10.1136/thorax-2021-218360. Epub 2022 Oct 25.
3
Longitudinal changes to quadriceps thickness demonstrate acute sarcopenia following admission to hospital for an exacerbation of chronic respiratory disease.纵向的股四头肌厚度变化表明，慢性呼吸道疾病加重住院后会出现急性肌少症。
Thorax. 2021 Jul;76(7):726-728. doi: 10.1136/thoraxjnl-2020-215949. Epub 2020 Dec 22.
4
Sarcopenia in COPD: a systematic review and meta-analysis.COPD 中的肌肉减少症：系统评价和荟萃分析。
Eur Respir Rev. 2019 Nov 13;28(154). doi: 10.1183/16000617.0049-2019. Print 2019 Dec 31.
5
Review of Drug Development Guidance to Treat Chronic Obstructive Pulmonary Disease: US and EU Perspectives.药物开发指导治疗慢性阻塞性肺疾病的综述：美国和欧盟的观点。
Clin Pharmacol Ther. 2019 Dec;106(6):1222-1235. doi: 10.1002/cpt.1540. Epub 2019 Jul 23.
6
Development of Pharmacotherapies for the Treatment of Sarcopenia.用于治疗肌肉减少症的药物疗法的开发。
J Frailty Aging. 2019;8(3):120-130. doi: 10.14283/jfa.2019.11.
7
Sarcopenia: revised European consensus on definition and diagnosis.肌少症：定义和诊断的欧洲共识修订版。
Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169.
8
Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial.抑素Ⅱ型受体阻断剂治疗慢性阻塞性肺疾病肌肉消耗：一项随机试验。
Am J Respir Crit Care Med. 2019 Feb 1;199(3):313-320. doi: 10.1164/rccm.201802-0286OC.
9
EQ-5D and the EuroQol Group: Past, Present and Future.EQ-5D与欧洲生活质量小组：过去、现在与未来。
Appl Health Econ Health Policy. 2017 Apr;15(2):127-137. doi: 10.1007/s40258-017-0310-5.
10
Management of chronic obstructive pulmonary disease beyond the lungs.肺部之外的慢性阻塞性肺疾病管理。
Lancet Respir Med. 2016 Nov;4(11):911-924. doi: 10.1016/S2213-2600(16)00097-7. Epub 2016 Jun 2.
Zotero 插件